Clinical Trials
75 trialsIpilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
European Institute of Oncology
SNMM
Eye & ENT Hospital of Fudan University
A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)
RemeGen Co., Ltd.
OpACIN-neo
The Netherlands Cancer Institute
RegoMel
Universitair Ziekenhuis Brussel
Neo Trio
Melanoma Institute Australia
CAcTUS
The Christie NHS Foundation Trust
Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma
Fudan University
To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma
Fudan University
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Shanghai Kechow Pharma, Inc.
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
Qilu Pharmaceutical Co., Ltd.
Effect of Topical Application of Hypertonic Saline on Melanoma on Its Sizes and Number.
Batroussy, Rafik
The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma
Fudan University
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
Hoosier Cancer Research Network
Keynote-695
OncoSec Medical Incorporated
(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma
Leiden University Medical Center
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
OBERTON
Biocad
Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma
Fujian Cancer Hospital
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
California Pacific Medical Center Research Institute
To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
Peking University Cancer Hospital & Institute
Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
Fudan University
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Sunnybrook Health Sciences Centre
REFINE
University College, London
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)
Samsung Medical Center
Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
Peking University Cancer Hospital & Institute
PREMIUM
Cambridge University Hospitals NHS Foundation Trust
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
California Pacific Medical Center Research Institute
Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
The First Hospital of Jilin University
Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy
Blokhin's Russian Cancer Research Center
A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma
First Affiliated Hospital of Zhejiang University
Zirconipi
Amsterdam UMC, location VUmc
Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
Yonsei University
Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
Jewish General Hospital
A Study of HX008 for the Treatment of Patients With Malignant Melanoma
Taizhou Hanzhong biomedical co. LTD
Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract
Fudan University
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma
Shanghai Junshi Bioscience Co., Ltd.
MIRACULUM
Biocad
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma
Peking University Cancer Hospital & Institute
A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients
OrienGene Biotechnology Ltd.
NIBIT-ML1
Italian Network for Tumor Biotherapy Foundation
OPTIMAL
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma
Yonsei University
PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma
Peking University Cancer Hospital & Institute
Nab-PCE vs PC for MM After Failure of Anti-PD-1
Peking University Cancer Hospital & Institute
Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma
Syneos Health
Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy
Hadassah Medical Organization
Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations
Peking University Cancer Hospital & Institute
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma
Henan Cancer Hospital